Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Paying $1,200 a month for the name-brand drug Zepbound wasn’t sustainable, and it was becoming impossible to find, she said. And she’s not alone. Readdy turned to online communities where ...

Kailey Wright delayed filling a prescription for Zepbound injection pens after her pharmacy told her she would have to pay about $600 out of pocket for a month’s supply because her employer ...

Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days. They're in short supply, and often too expensive to afford without insurance coverage. Advertisement ...

Express Scripts, one of the country’s largest pharmacy benefit managers, sued the Federal Trade Commission (FTC) Tuesday and demanded the agency retract a report saying the industry middlemen ...

It’s a field that’s already undergoing a revolution, with millions of people across the US now using semaglutide and tirzepatide, sold as Wegovy and Zepbound for weight loss (and for diabetes ...

Tirzepatide is a more expensive and slightly more effective antidiabetic weight-loss injection sold under the brand names Mounjaro and Zepbound. The drugs are typically self-administered ...

The recent surge in optimism about the stock is mainly attributed to strong sales of three key products: Mounjaro, Zepbound, and Verzenio. Sales for the popular breast cancer medication Verzenio ...